-
New Psoriasis Treatment Yields Favorable Safety, Efficacy Profile
CME A new monoclonal antibody used for treatment of psoriasis was generally well tolerated for up to 3 years of follow-up; most adverse events were mild and did not require treatment discontinuation.
Medscape Education Clinical Briefs, March 2012
-
Updated Plaque Psoriasis Guidelines Released
CME/CE The National Psoriasis Foundation Medical Board reviewed and updated the Canadian Guidelines for the Management of Plaque Psoriasis; they reflect practice patterns in the United States.
Medscape Education Clinical Briefs, January 2012
-
New Meta-Analysis Summarizes Effectiveness of Psoriasis Treatments
CME Results from clinical trials of psoriasis treatments suggest that combination therapies may be more effective, tolerable, and have fewer combined adverse effects than monotherapies.
Medscape Education Clinical Briefs, December 2011
-
FDA Safety Changes: TNF Blockers Require Increased Surveillance
CME/CE The FDA has issued a notice to manufacturers of tumor necrosis factor-alpha blockers to increase their surveillance because of possible cancer risk in children and adults younger than 30 years.
Medscape Education Clinical Briefs, November 2011
-
Management of Psoriatic Arthritis From the View of the Dermatologist
CME What is the best practice in the evaluation and management of psoriatic arthritis? The current review addresses these issues.
Nature Reviews Rheumatology, October 2011
-
FDA Safety Changes: TNF Blockers Receive Updated Boxed Warning of Risk for 2 Fatal Bacterial Infections
CME/CE The FDA issued that all tumor necrosis factor-alpha inhibitors receive a boxed warning to warn of the risk for serious and sometimes fatal infection from bacterial pathogens Legionella and Listeria.
Medscape Education Clinical Briefs, September 2011
-
Biologic Therapies in Non-rheumatic Diseases: Lessons for Rheumatologists?
CME How effective and safe are biologic therapies for nonrheumatic diseases? The current review evaluates this issue.
Nature Reviews Rheumatology, September 2011
-
Biologics for Psoriasis Not Associated With Increased Cardiovascular Events
CME Specific biologic agents for plaque psoriasis were not linked with a significant difference in adverse cardiovascular event rates vs placebo, but the study may have lacked statistical power.
Medscape Education Clinical Briefs, August 2011
-
Phototherapy and Photochemotherapy in Childhood Psoriasis
CME Are photo- and photochemotherapy appropriate treatments for children and adolescents with psoriasis? The current review explores this issue.
Expert Review of Dermatology, August 2011
-
DMARDs May Alter Risk for Diabetes in Patients With RA or Psoriasis
CME/CE The risk for diabetes was reduced in patients receiving a tumor necrosis factor inhibitor or hydroxychloroquine vs those taking other nonbiologic disease-modifying antirheumatic drugs.
Medscape Education Clinical Briefs, June 2011
-
Adult Outcomes of Childhood-Onset Rheumatic Diseases
How do rheumatic diseases diagnosed and treated during childhood affect adult health? The current review answers this question.
Nature Reviews Rheumatology, May 2011
-
Prevalence of Metabolic Syndrome Increased in Persons With Psoriasis
A health survey showed high prevalence of the metabolic syndrome among individuals with psoriasis; this comorbidity should be considered in long-term treatment.
Medscape Education Clinical Briefs, December 2010
-
Risk for Psychiatric Conditions May Be Increased in Patients With Psoriasis
In a population-based cohort study, patients with psoriasis had an increased risk for depression, anxiety, and suicidality.
Medscape Education Clinical Briefs, August 2010
-
Beer Drinking Increases Risk for Psoriasis in Women
Women who drink regular beer, but not light beer, increase their risk for the development of psoriasis. Other types of alcohol do not appear to be associated with this risk.
Medscape Education Clinical Briefs, August 2010
-
Obesity at Age 18 Years Linked to Greater Risk for Psoriatic Arthritis
In a case series, adiposity was associated with higher levels of inflammatory cytokines involved in psoriasis; early management of obesity may decrease the risk for psoriatic arthritis.
Medscape Education Clinical Briefs, July 2010
-
Ustekinumab Superior to Etanercept in Treating Moderate to Severe Psoriasis
Reaching a 90% improvement score was more common among those who received ustekinumab, but both drugs were able to achieve at least 50% improvement in all patients.
Medscape Education Clinical Briefs, January 2010
-
The Treatment of Moderate-to-Severe Plaque Psoriasis: A Case-Based Expert Interview With Kenneth B. Gordon, MD
Follow the case of a young woman with plaque psoriasis affecting 40% of her body
Medscape Education Dermatology, January 2010
-
Special Report: The Topical Treatment of Psoriasis, Volume 4
A recent conference brought together clinicians and basic scientists to explore the relationship between atherosclerosis and psoriasis.
Medscape Education Dermatology, November 2009
-
Advances in Immune Inflammatory Rheumatic Diseases: An Expert Interview With Joseph A. Markenson, MD
Dr. Joseph A. Markenson discusses the latest advances in the understanding of the pathophysiology of immune inflammatory rheumatic diseases and their clinical implications.
Medscape Education Rheumatology, November 2009
-
The Diagnosis and Treatment of Early Psoriatic Arthritis
PsA presents in varied and unpredictable ways in patients with psoriasis, but the recent availability of more sensitive imaging studies for diagnosis and biologic agents for treatment has the potential to allow early diagnosis and treatment to slow disease progression.
Nature Reviews Rheumatology, November 2009
-
Bridging Dermatology and Rheumatology: Psoriatic Arthritis Case Study
Review strategies to diagnose psoriatic arthritis, to evaluate the safety and efficacy of treatment options, and to optimize interdisciplinary exchanges in caring for these patients.
October 2009
